Notice of First Quarter 2023 Results

Dial in details for the presentation are detailed below. Dial in details for the presentation are detailed below. Webcast Link: https://webcast.openbriefing.com/pharming1q23/ Conference Call Dial-in Details: Netherlands : +31 85 888 7233United Kingdom(Local): +44 20 3936 2999United Kingdom(Toll-Free): +44 808 189 0158United States(Local): +1 646 664 1960United States(Toll-Free): +1 855 979 6654 Global Dial-In Numbers   Access Code: 598957 About...

Dial in details for the presentation are detailed below.

Webcast Link:

https://webcast.openbriefing.com/pharming1q23/

Conference Call Dial-in Details:
Netherlands: +31 85 888 7233
United Kingdom (Local): +44 20 3936 2999
United Kingdom (Toll-Free): +44 808 189 0158
United States (Local): +1 646 664 1960
United States (Toll-Free): +1 855 979 6654

Global Dial-In Numbers 

Access Code: 598957

About Pharming Group N.V.

Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:

Pharming Group, Leiden, The Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696

Heather Robertson, Investor Relations & Corporate Communications Manager
E: [email protected] 

FTI Consulting, London, UK 
Victoria Foster Mitchell/ Alex Shaw/Amy Byrne 
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands 
Leon Melens 
T: +31 6 53 81 64 27 E: [email protected]

Logo: https://mma.prnewswire.com/media/2003587/Pharming_Group_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/notice-of-first-quarter-2023-results-301801417.html